Literature DB >> 1534827

Design and synthesis of a self-assembling peptide derived from the envelope proteins of HIV type 1. An approach to heterovalent immunogens.

S P Tripathy1, A Kumar, V Manivel, S K Panda, K V Rao.   

Abstract

A chimeric peptide that included sequences from gp120 and gp41 of HIV type 1 was synthesized. Cleavage from solid support yielded a composite of self-oligomerized products with molecular masses ranging from 5 to about 9 kDa. The oligomer but not its reduced, monomeric form was recognized by human anti-HIV sera and at least one of the two lysines in the sequence was involved in antibody binding. The oligomeric peptide was immunogenic, yielding a conformation-specific antibody response. Co-oligomerization of a hepatitis B surface Ag-derived peptide and the HIV type 1-derived peptide yielded a bivalent product in which conformational integrity of the individual components was maintained. Immunization with this hybrid peptide resulted in conformation-specific antibodies to both epitopes in all four murine strains tested. Lymphocyte proliferation assays revealed that the T epitopes resident in both peptide sequences remained active in the hybrid peptide. These results demonstrate the potential of this approach in generating multi- and heterovalent immunogens which may eventually find application as vaccines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534827

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen.

Authors:  A Mishra; K V Rao; H Durgapal; V Manivel; S K Panda
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

2.  An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain.

Authors:  J S Wolinsky; E Sukholutsky; W T Moore; A Lovett; M McCarthy; B Adame
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.